(E/Z)-BCI

TargetMol
Product Code: TAR-T11139
Supplier: TargetMol
CodeSizePrice
TAR-T11139-1mg1mg£168.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11139-5mg5mg£270.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11139-1mL1 mL * 10 mM (in DMSO)£305.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11139-10mg10mg£468.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11139-25mg25mg£706.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11139-50mg50mg£970.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11139-100mg100mg£1,267.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11139-500mg500mg£2,456.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
(E/Z)-BCI attenuates LPS-induced inflammatory mediators and ROS production in macrophage cells via activating the Nrf2 signaling axis and inhibiting the NF-κB pathway. (E/Z)-BCI is a dual-specificity phosphatase 6 (DUSP6) inhibitor with anti-inflammatory activities.
CAS:
15982-84-0
Formula:
C22H23NO
Molecular Weight:
317.432
Pathway:
Apoptosis; Metabolism
Purity:
0.9855
SMILES:
O=C1C(=C/c2ccccc2)C(NC2CCCCC2)c2ccccc12
Target:
Apoptosis; Phosphatase

References

1. Zhang F, et al. DUSP6 Inhibitor (E/Z)-BCI Hydrochloride Attenuates Lipopolysaccharide-Induced Inflammatory Responses in Murine Macrophage Cells via Activating the Nrf2 Signaling Axis and Inhibiting the NF-?B Pathway. Inflammation. 2019 Apr;42(2):672-681. 2. Wu QN,et al. Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance. Cancer Lett. 2018 Jan 1;412:243-255.